Improving access to novel agents for childhood leukemia.

about

Synthesis and Anti-Proliferative Activity of Sulfanyltriazolylnaphthalenols and Sulfanyltriazolylnaphthalene-1,4-diones.Factors Associated with Emotional Distress in Children and Adolescents during Early Treatment for Cancer

P2860

Q38758576-DE24020D-DF4E-4B54-A46A-C4E54171B294 Q39328402-FA4368EC-40EA-4715-ACB4-741C8F4A86EE

P2860

Improving access to novel agents for childhood leukemia.

Item

http://www.wikidata.org/entity/Q35688742

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Improving access to novel agents for childhood leukemia.

@ast

Improving access to novel agents for childhood leukemia.

@en

type

Item

label

Improving access to novel agents for childhood leukemia.

@ast

Improving access to novel agents for childhood leukemia.

@en

prefLabel

Improving access to novel agents for childhood leukemia.

@ast

Improving access to novel agents for childhood leukemia.

@en

P1476

Improving access to novel agents for childhood leukemia.

@en

P2093

Alan S Wayne

http://www.w3.org/2001/XMLSchema#string

Richard Sposto

http://www.w3.org/2001/XMLSchema#string

Weili Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Drug development: Raise standards for preclinical cancer research

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Selecting the best drugs for phase I clinical development and beyond

Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale

Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.

The price of innovation: new estimates of drug development costs

Estimating the cost of new drug development: is it really 802 million dollars?

Believe it or not: how much can we rely on published data on potential drug targets?

Chimeric antigen receptor T cells for sustained remissions in leukemia

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

P304

1927-1936

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.29267

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

Paul S. Gaynon

P577

2015-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25678105

http://www.w3.org/2001/XMLSchema#string

P932

4457598

http://www.w3.org/2001/XMLSchema#string

Improving access to novel agents for childhood leukemia.

about

P2860

P2860

Improving access to novel agents for childhood leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932